Mice treated with CS-EGF-Lip exhibited significantly increased antitumor activity, enhanced delivery of cisplatin into ovarian tumor tissues and decreased nephrotoxicity compared to the other treatment groups (137). This evidence concerns the gene EGF and ovarian neoplasm.